StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report sent to investors on Wednesday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Price Performance
Shares of TTNP stock opened at $5.57 on Wednesday. The company’s fifty day simple moving average is $6.67 and its 200-day simple moving average is $6.82. Titan Pharmaceuticals has a 52 week low of $5.00 and a 52 week high of $13.97.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last issued its earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($1.24) EPS for the quarter. Titan Pharmaceuticals had a negative net margin of 2,014.71% and a negative return on equity of 99.96%.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Articles
- Five stocks we like better than Titan Pharmaceuticals
- Investing In Preferred Stock vs. Common Stock
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- How to Most Effectively Use the MarketBeat Earnings Screener
- MarketBeat Week in Review – 6/24 – 6/28
- What is the Hang Seng index?
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.